Last reviewed · How we verify

NCT03957512

Livet Skal Leves (A Life to Live)

Completed Last updated 22 May 2019
What this trial tests

trial testing Heart surgery in Heart Defects, Congenital in 3,000 participants. Completed in 31 December 2018.

Timeline
1 October 2017
Primary endpoint
31 December 2017
31 December 2018

Quick facts

Lead sponsorOslo University Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment3,000
Start date1 October 2017
Primary completion31 December 2017
Estimated completion31 December 2018
Sites1 location across Norway

Drugs / interventions tested

Conditions studied

Sponsor

Oslo University Hospital

Who can join

Under 2, any sex, with Heart Defects, Congenital. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overall objective of this project is to optimize the use of diagnostic methods and follow-up programs in infants with congenital heart defects (CHDs) in order to reduce death and complications

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Heart surgery

Trials testing the same drug.

Other recruiting trials for Heart Defects, Congenital

Currently open trials in the same condition.

Other Oslo University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03957512.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing